Cooper Companies posted strong Q2 growth, with earnings and free cash flow improving despite a litigation charge. CooperVision remains the steady core, while CooperSurgical adds strategic upside after major recall claims were largely resolved.
The Cooper Companies(COO) is a solid medium-term compounder with a messy headline and a better underlying business than the headline implies. The core case rests on three hard facts. First, fiscal Q2 2026 revenue reached $1.082B, up 8% year over year, while non-GAAP EPS rose 26% to $1.21. Second, CooperVision remains the larger and steadier engine, generating $2.744B of fiscal 2025 revenue and holding roughly one-third of global contact lens wearers according to management. Third, CooperSurgical is attracting significant strategic interest after the company resolved settlements with over 95% of claimants tied to the embryo culture media recall, which removes a major overhang even though the quarter absorbed a $271.6M litigation-related charge.
That combination creates an unusual setup. The operating business is still growing, free cash flow is improving, and management reaffirmed full-year non-GAAP EPS guidance of $4.58 to $4.66 while increasing 2026 free cash flow guidance to roughly $650M excluding litigation payouts. Yet the stock still carries a trailing P/E of 30.9 and a forward P/E of 13.2, a gap that reflects how distorted trailing earnings are by one-time noise. For a balanced, moderate-risk investor, COO looks more like a Buy than a swing-for-the-fences story: the business quality is real, the balance sheet is manageable, and the strategic review around CooperSurgical adds optionality, but APAC softness, tariffs, and recall-related scars keep this from being a clean premium multiple story.
The Cooper Companies(COO) is a healthcare supplies company headquartered in San Ramon, California, with about 15,000 employees. It operates through two businesses: CooperVision, which sells soft contact lenses and myopia management products, and CooperSurgical, which sells fertility products and services, medical devices, contraception, and cryostorage offerings. Fiscal year end is October.
Scale is meaningful but not bloated. Fiscal 2025 revenue was $4.09B, up from $3.90B in fiscal 2024 and $3.59B in fiscal 2023. Over the last decade, management says company revenue has more than doubled, and the investor presentation shows CooperVision at a 10-year revenue CAGR of 6.3% and CooperSurgical at 15.9%. That is a useful clue to the shape of the business: CooperVision is the durable base, while CooperSurgical has been the faster-growing bolt-on and portfolio-building arm.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →The latest quarter also showed why the company can be misunderstood. GAAP EPS for fiscal Q2 2026 was $(0.40), versus $0.44 a year earlier, because of the $271.6M litigation-related charge. But the operating picture was much stronger. Revenue hit a record $1.082B, operating income increased 19%, and non-GAAP EPS reached $1.21. In plain English, the engine is running; the dashboard just has a warning light from an old accident.
CooperVision is the main profit and scale driver. In fiscal 2025, it produced $2.7438B of revenue, or 67% of total company sales. In fiscal Q2 2026, segment revenue was $723.5M, up 8% reported and 4% organically. Management said the Americas grew 7% and EMEA grew 6%, while Asia Pacific declined 6% as the company continued to rationalize legacy hydrogel products and faced weaker-than-expected conditions in Japan and China.
That market position matters because contact lenses are recurring consumables, and practitioner fit habits are sticky. CooperVision’s fiscal 2025 category mix also shows a healthy skew toward more specialized products: toric and multifocal lenses generated $1.351B, up 7%, while sphere and other generated $1.393B, up 3%. The faster growth in toric and multifocal is important because those are harder categories to commoditize.
CooperSurgical is smaller at 33% of fiscal 2025 revenue, but it is strategically important. Fiscal 2025 revenue was $1.3486B, up from $1.286B in fiscal 2024. In fiscal Q2 2026, segment revenue reached $358M, up 8% reported and 6% organically. Within that, fertility grew 10% organically to $144M, while office and surgical products and services reached $214M, up 4%. The investor presentation shows CooperSurgical’s fiscal 2025 mix at 39% fertility and 61% office and surgical.
The strategic review is the wild card. CEO Al White said the company has received significant indications of interest in CooperSurgical, including for the entire business, after resolving substantially all recall-related claims. That does not guarantee a transaction, but it does put a market test on the value of an asset that management clearly believes is underappreciated inside the current structure.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CooperVision’s flagship products are doing the heavy lifting. MyDay, the premium 1-day silicone hydrogel lens family, delivered double-digit growth in fiscal Q2 2026 as daily silicone hydrogel lenses grew 8%. Management tied that performance to expanding customer partnerships and premium product demand. In a contact lens market that management sizes at about $11B globally, premium daily silicone hydrogel is the lane with the best mix of growth and pricing power.
Biofinity remains another anchor product. Management called it the highest grossing product in the business context and said it grew 5% organically in Q2 2026, led by toric and multifocal lenses. The more interesting detail is not just growth but fit breadth. Cooper said Biofinity offers more than 6x the prescription options of all other monthly brands combined. That is not marketing fluff. In practitioner-driven categories, broad parameter coverage is a moat because it reduces the need to switch brands when a patient falls outside standard ranges.
MiSight is the most strategically valuable growth product. Fiscal Q2 2026 revenue rose 24% to $32M after growing 23% to $28M in fiscal Q1 2026. The 10-K states MiSight 1 day is the first and only FDA-approved contact lens indicated to slow myopia progression in children, with approvals also in China and Japan. That regulatory position gives COO a differentiated niche in pediatric eye care, where clinical validation matters more than a few points of price.
On the CooperSurgical side, Paragard remains a notable branded asset. The investor presentation calls it the #1 non-hormonal IUD, with a 10-year indication and 99% effectiveness, and notes that the FDA-approved single-hand inserter launched in 2025. In fiscal Q2 2026, Paragard delivered flat revenue but still came in ahead of management expectations. Flat is not exciting, but in contraception, durable relevance is often more valuable than flashy growth.
COO’s competitive advantage comes from product breadth, regulatory positioning, and manufacturing know-how rather than from brute scale. The 10-K says the company protects its products through patents, trademarks, trade secrets, licenses, technical know-how, and continuing technological innovation. That matters because both contact lenses and fertility products sit in categories where quality failures are expensive and regulatory barriers are real.
In CooperVision, the moat is especially visible in three places. First, MiSight has a differentiated clinical and regulatory profile in myopia management. Second, Biofinity’s parameter breadth makes it easier for eye care practitioners to fit a wide range of patients without changing brands. Third, the company has a full silicone hydrogel offering across daily and frequent replacement modalities, which is important as the market shifts away from older hydrogel products.
In CooperSurgical, the edge is portfolio breadth and workflow integration. Management highlighted Witness, its automated lab tracking system, as a source of global momentum in fertility. It also said capital equipment sales can create later consumable demand. That is a classic medtech playbook: place the equipment, then earn recurring revenue around it. When that works, it turns a one-time sale into a relationship.
The investor presentation also points to high barriers to entry, specialized manufacturing, technological expertise, and stringent FDA and global regulatory standards. Those claims line up with the business model. Contact lenses are not simple plastic discs, and fertility labs do not casually switch vendors on a whim. This is a business where trust, fit success, and supply reliability carry real economic value.
Operations improved materially in the latest quarter. Gross margin in fiscal Q2 2026 was 68.1%, roughly flat year over year, while operating expenses rose just 1%. That allowed operating income to increase 19% and operating margin to reach 27.5%. Management credited last year’s reorganization, back-office consolidation, and efficiency initiatives, especially within CooperSurgical, where expenses declined year over year for the second consecutive quarter.
Supply chain execution is becoming a bigger part of the story. CFO Brian Andrews said a new AI-enhanced inventory control system is allowing the company to reduce inventory levels. That has two effects. It pressures gross margin in the near term because of lower production at CooperVision, but it helps free cash flow. Management reaffirmed a 2026 to 2028 free cash flow objective of more than $2.2B and raised fiscal 2026 free cash flow guidance to roughly $650M excluding litigation payouts.
There are still cost headwinds. Guidance assumes about $22M of tariff impact in fiscal 2026, with possible refunds of as much as $15M not included. Management also flagged higher freight costs and unfavorable FX. This is a reminder that COO is global and exposed to the usual medtech plumbing risks. The company can manage around them, but it cannot pretend they do not exist.
COO operates in two attractive markets with different growth profiles. In contact lenses, management says the global market is about $11B and growing at a mid-single-digit rate annually. The best pockets are premium daily silicone hydrogel, torics, multifocals, and myopia management. Those are exactly the categories where CooperVision is leaning hardest, and the fiscal 2025 growth split supports that strategy: toric and multifocal grew 7%, while sphere and other grew 3%.
The fertility and women’s health market also offers durable demand drivers. Management cited delayed childbirth, improving IVF access, and increasing clinic investments in technology and workflow optimization. In fiscal Q2 2026, fertility grew 10% organically to $144M, and management said underlying fertility trends remain healthy with expected mid-single-digit growth in the back half of the year. California’s requirement that most large group health plans with over 100 employees cover IVF and infertility treatments starting in January adds a concrete policy tailwind.
There is one important wrinkle: Asia Pacific is weak right now for CooperVision. Management said Japan and China were softer than expected, and APAC revenue declined 6% in Q2 2026. That is not a thesis breaker because the Americas and EMEA remain healthy, but it does cap how aggressive an investor should get on near-term multiple expansion. A business can have a strong global franchise and still stub its toe in one region. Markets tend to notice the toe first.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
COO sells into professional channels where switching costs are higher than they look from the outside. CooperVision sells to distributors, eye care professionals, independent practices, corporate retailers, and authorized resellers. CooperSurgical sells to OB/GYN practices, hospitals, ambulatory surgery centers, fertility clinics, and direct-to-consumer channels for certain services. These are not impulse-buy categories. Product performance, fit success, clinical workflow, and supply reliability matter.
That customer mix helps explain why parameter breadth and service levels matter so much. An eye care practitioner wants a product family that can fit a broad patient base without forcing awkward substitutions. A fertility clinic wants equipment, consumables, and lab systems that work together and are supported well. COO’s customer profile favors vendors that reduce friction. In that sense, the company is selling fewer one-off products and more repeatable practice solutions.
The ownership base also reflects a professional-investor audience. Institutional ownership stands at 107.3% of shares outstanding, with Vanguard holding 23.5M shares and BlackRock holding 16.6M. Short interest is modest at 2.99% of float with a short ratio of 2.26. That is not the setup of a hated stock. It is the setup of a stock that institutions know well but are still debating.
CooperVision competes mainly against Johnson & Johnson Vision Care, Alcon, and Bausch + Lomb. Those peers are larger in some areas and have deeper pockets, which the 10-K acknowledges. COO’s answer is specialization. It competes on product quality, technological benefits, price, service levels, reliability, and broad SKU coverage. The company is not trying to out-conglomerate conglomerates. It is trying to be the fitter’s favorite.
CooperSurgical faces a more fragmented field. In fertility, the 10-K identifies Vitrolife Group, Nexpring, Fairfax Cryobank and Fairfax EggBank, and fertility clinics that provide their own services. In devices and women’s health, competitors include Johnson & Johnson, Baxter, Medtronic, Hologic, Bayer, AbbVie, and Organon. That sounds intimidating, but fragmentation can help a focused specialist if it has breadth in adjacent niches and trusted clinical relationships.
The biggest competitive risk is not that COO lacks good products. It is that larger rivals can spend more, bundle more, or pressure pricing. The 10-K also flags channel shifts toward direct-to-consumer fulfillment, online platforms, telemedicine, and online refractive exams. If practitioner economics change, lens makers need to adapt. COO has the product portfolio to compete, but it still has to keep up with how care is delivered.
The macro backdrop is mixed but manageable. On the positive side, both of COO’s end markets benefit from long-duration demand drivers. Myopia prevalence, premium lens trade-ups, delayed childbirth, and broader IVF access are structural trends rather than quarter-to-quarter fads. The company’s investor presentation explicitly frames the business around growth in wearers, myopia prevalence, geographic expansion, pricing, and the shift into 1-day silicone hydrogel lenses.
On the negative side, COO is exposed to FX, tariffs, and regional economic softness. Management said fiscal 2026 guidance includes about $22M of tariff costs and expects gross margin pressure from unfavorable FX, freight, and lower production tied to inventory optimization. Asia Pacific softness, especially in Japan and China, is another macro-sensitive issue. CEO Al White said the APAC market is softer than anticipated and that hydrogel rationalization could continue to pressure results through 2027.
Regulation is another real variable. The 10-K points to EU MDR and EU IVDR as material regulatory factors, and the recall-related litigation charge is a blunt reminder that quality and compliance failures can be expensive. In medtech, geopolitics often shows up less as a dramatic headline and more as a tariff, a freight bill, or a delayed approval. Those are quieter risks, but they still hit margins.
Net debt remains manageable, and the company’s improving free cash flow profile supports its ability to absorb litigation-related costs without derailing the core business.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Fiscal Q2 2026 revenue rose 8% to $1.082B and non-GAAP EPS jumped 26% to $1.21, even as GAAP EPS was pressured by a $271.6M charge.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management reaffirmed full-year non-GAAP EPS guidance of $4.58 to $4.66 and lifted 2026 free cash flow guidance to roughly $650M excluding litigation payouts.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →COO trades at a trailing P/E of 30.9 but a forward P/E of 13.2, showing how one-time noise is distorting the headline multiple.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s valuation framework points to $92 as fair value, with upside and downside bands spanning $78 for Buy and $102 for Sell.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The Cooper Companies(COO) is not a perfect story, but it is a good business. The latest quarter showed record revenue of $1.082B, non-GAAP EPS growth of 26%, and continued strength in premium contact lenses, myopia control, and fertility. It also showed that the company can absorb a major litigation charge and still keep the operating machine moving. That is the sort of resilience investors should notice.
For the medium-term investor, the appeal is discipline rather than drama. CooperVision gives COO a recurring, globally scaled core. CooperSurgical adds growth and strategic optionality. Free cash flow is improving, debt is manageable, and insider transaction data shows net buying of 33,989 shares in the tracked period. The stock does not need heroics to work from here. It just needs the company to keep doing what it has largely done already: execute, simplify the story, and let the quality of the business show through the noise.
The Cooper Companies, Inc. (COO) rises after posting a strong quarterly beat and lifting full-year earnings guidance. Investors responded to solid contact lens demand, improved profitability, and heavier trading volume, signaling renewed confidence in the healthcare stock’s outlook.
These seven crypto treasury stocks span infrastructure, mining, and pure bitcoin accumulation, with MSTR and RIOT standing out most on overall quality and thematic relevance.
U.S. hiring surprised to the upside in May, with payrolls rising 172,000 and unemployment holding at 4.3%. Job openings also jumped sharply, signaling resilient labor demand even as claims and quits suggest the market is cooling from its hottest pace.